PARP Inhibitors Drug Therapy Market by Drug, Indication, Distribution Channel

Description

List of Tables

[189 Pages Report] The PARP Inhibitors Drug Therapy Market size was estimated at USD 6.73 billion in 2023 and expected to reach USD 7.32 billion in 2024, at a CAGR 9.15% to reach USD 12.43 billion by 2030.

Global PARP Inhibitors Drug Therapy Market

KEY MARKET STATISTICS
Base Year [2023]	USD 6.73 billion
Estimated Year [2024]	USD 7.32 billion
Forecast Year [2030]	USD 12.43 billion
CAGR (%)	9.15%

PARP Inhibitors Drug Therapy Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the PARP Inhibitors Drug Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the PARP Inhibitors Drug Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the PARP Inhibitors Drug Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Artios Pharma Limited, AstraZeneca PLC, BeiGene, Inc., Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline PLC, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Company Ltd., Johnson & Johnson Services, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Repare Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the PARP Inhibitors Drug Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug
- Niraparib
- Olaparib
- Rucaparib
- Talazoparib
Indication
- Breast Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the PARP Inhibitors Drug Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the PARP Inhibitors Drug Therapy Market?

3. What are the technology trends and regulatory frameworks in the PARP Inhibitors Drug Therapy Market?

4. What is the market share of the leading vendors in the PARP Inhibitors Drug Therapy Market?

5. Which modes and strategic moves are suitable for entering the PARP Inhibitors Drug Therapy Market?

Product Code: MRR-AD517FAA718F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. PARP Inhibitors Drug Therapy Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of cancers
  - 5.1.1.2. Growing numbers of clinical trials worldwide
  - 5.1.1.3. Elevation in government approvals for PARP drugs
- 5.1.2. Restraints
  - 5.1.2.1. High cost of treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research and development projects to introduce novel drug therapies
  - 5.1.3.2. Governmental programs to enhance the cancer treatment therapies
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with side effects of drug therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. PARP Inhibitors Drug Therapy Market, by Drug

6.1. Introduction
6.2. Niraparib
6.3. Olaparib
6.4. Rucaparib
6.5. Talazoparib

7. PARP Inhibitors Drug Therapy Market, by Indication

7.1. Introduction
7.2. Breast Cancer
7.3. Ovarian Cancer
7.4. Pancreatic Cancer
7.5. Prostate Cancer

8. PARP Inhibitors Drug Therapy Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies

9. Americas PARP Inhibitors Drug Therapy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific PARP Inhibitors Drug Therapy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. AbbVie Inc.
- 13.1.2. Artios Pharma Limited
- 13.1.3. AstraZeneca PLC
- 13.1.4. BeiGene, Inc.
- 13.1.5. Bristol-Myers Squibb Company
- 13.1.6. Clovis Oncology
- 13.1.7. GlaxoSmithKline PLC
- 13.1.8. IMPACT Therapeutics
- 13.1.9. Jeil Pharmaceuticals Co. Ltd.
- 13.1.10. Jiangsu Hengrui Pharmaceuticals Company Ltd.
- 13.1.11. Johnson & Johnson Services, Inc.
- 13.1.12. Karyopharm Therapeutics
- 13.1.13. Merck & Co., Inc.
- 13.1.14. Ono Pharmaceutical Co., Ltd.
- 13.1.15. Pfizer Inc.
- 13.1.16. Repare Therapeutics, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing